BACKGROUND:  Cancer is the result of cumulative multiple genetic mutations, which result in the activation of oncogenes and/or the inactivation of tumor suppressor genes. With advances in the understanding of tumor biology at the molecular and cellular level, it has been recognized that targeted therapies tailored for individual tumors need to be developed.

Although advances have been made in detection and therapy of these diseases, no universally successful method for prevention or treatment is currently available. Current therapies, which are generally based on a combination of surgery and radiation or chemotherapy, continue to prove inadequate in many patients.

INNOVATION:  UCLA scientists have discovered a new proto-oncogene, GDOX, which is overexpressed in various human cancers. GDOX provides a novel target for treatment and detection of cancer. Using both in vitro and in vivo techniques, it has been demonstrated that antibodies and anti-sense nucleotides directed against GDOX are effective in inhibiting proliferation of cancer cells derived from multiple tissues, including brain, breast, lung, colon and prostate. This invention provides GDOX-related molecules as diagnostic and therapeutic agents for the detection, monitoring and treatment of various cancers.

POTENTIAL APPLICATIONS 

• Treatment of cancers overexpressing GDOX
• Detection and monitoring of cancers overexpressing GDOX
• Cancer vaccines based on GDOX antigens

ADVANTAGES

• Validity of target has been demonstrated with both antibody and siRNA methods
• GDOX is differentially expressed in cancer cells compared to normal cells

Reference: UCLA Case No. 2000-479

US Patent Number: 7,204,982